Dr. Sarah Ronnebaum is a Senior Scientist in Strategic Market Access, located in Pharmerit’s Bethesda, Maryland office. Her expertise includes systematic and targeted literature reviews, value messaging, and dossiers. Sarah has therapeutic experience in the following areas: cardiovascular disease, oncology, diabetes, aging, infectious disease, addiction, neurological disorders, muscular disorders, and various rare diseases.
Prior to joining Pharmerit, Sarah worked as a Senior Consultant at Deloitte Consulting in Arlington, Virginia across a breadth of roles including strategic planning, stakeholder engagement, and strategy implementation for the National Institutes of Health, Department of Defense, and other federal agencies. Additionally, Sarah served and led projects in the Translational Medicine Group at Deloitte. Sarah was also a postdoctoral fellow and research associate at the University of North Carolina, where she published 7 articles on protein homeostasis mechanisms in major journals. Sarah earned a BS in Pharmaceutical Sciences and a BA in biology from Drake University, then earned a PhD in Pharmacology from Duke University.